RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
1 . A compound comprising:
I) a double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of a target gene via RNA interference, comprising a sense strand and an antisense strand, said siNA molecule comprising formula (A):
wherein, the upper strand is the sense strand and the lower strand is the antisense strand of the siNA molecule; wherein the antisense strand comprises a sequence having at least 15 nucleotides that are complementary to a target RNA sequence encoded by the target gene and the sense strand comprises a sequence that is complementary to the antisense strand; each N is independently a nucleotide which is unmodified or chemically modified, or is a non-nucleotide; each B is independently a terminal cap; (N) represents overhanging nucleotides, each of which is independently unmodified or chemically modified; [N] represents nucleotides at the 5′-terminus of the antisense strand; X1 and X2 are independently integers from 0 to 4; X3 is an integer from 15 to 30; X4 is an integer from 12 to 27; and X5 is an integer from 1-6, provided that the sum of X4 and X5 is an integer from 15-30; and wherein
(a) five or more pyrimidine nucleotides in N X4 positions are a combination of two or more of independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl nucleotides, 2′deoxy nucleotides, ribonucleotides, or any combination thereof;
(b) five or more purine nucleotides in N X4 positions are independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl nucleotides, 2′deoxy nucleotides, ribonucleotides, or any combination thereof;
(c) five or more pyrimidine nucleotides in N X3 positions are independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl nucleotides, 2′deoxy nucleotides, ribonucleotides, or any combination thereof;
(d) five or more purine nucleotides in N X3 positions are independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl nucleotides, 2′deoxy nucleotides, ribonucleotides;
(e) [N] position nucleotide(s) are ribonucleotides, deoxyribonucleotides, 2′-O-alkyl nucleotides, or 2′-halo nucleotides, or any combination thereof irrespective of purine or pyrimidine content; and
(f) the nucleotide at position 14 from the 5′-end of the antisense strand is a 2′-deoxy-2′-fluoro nucleotide regardless of whether it is a purine or pyrimidine; and
II) a ligand covalently attached to the siNA molecule.
2 . The compound according to claim 1 , wherein each B is an inverted abasic moiety.
3 . The compound according to claim 2 , wherein:
(a) five or more pyrimidine nucleotides in N X4 positions are 2′-O-methyl nucleotides;
(b) five or more purine nucleotides in N X4 positions are 2′-deoxy-2′-fluoro nucleotides;
(c) five or more pyrimidine nucleotides in N X3 positions are 2′-O-methyl nucleotides;
(d) five or more purine nucleotides in N X3 positions are 2′-deoxy-2′-fluoro nucleotides; and
(e) [N] position nucleotide(s) are any combination of ribonucleotides, deoxyribonucleotides, 2′-O-alkyl nucleotides, or 2′-halo nucleotides.
4 . The compound according to claim 2 , wherein:
(a) 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides in N X4 positions are 2′-O-methyl nucleotides;
(b) 5, 6, 7, 8, 9, 10 or more purine nucleotides in N X4 positions are 2′-deoxy-2′-fluoro nucleotides;
(c) 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides in N X3 positions are 2′-O-methyl nucleotides;
(d) 5, 6, 7, 8, 9, 10 or more purine nucleotides in N X3 positions are 2′-deoxy-2′-fluoro nucleotides; and
(e) [N] position nucleotide(s) are any combination of ribonucleotides, deoxyribonucleotides, 2′-O-alkyl nucleotides, or 2′-halo nucleotides.
5 . The compound according to claim 2 , wherein X5 is 3.
6 . The compound according to claim 5 , wherein the three [N] nucleotides of formula (A) are represented as 5′-[N1, N2, N3]-3′, wherein:
a. each N1, N2, and N3 is a ribonucleotide; or
b. each N1, N2, and N3 is a 2′-deoxy-2′-fluoro nucleotide; or
c. each N1, N2, and N3 is a 2′-deoxy nucleotide; or
d. each N1, N2, and N3 is a 2′-O-alkyl nucleotide; and
e. any of N1, N2, or N3 optionally comprises a phosphorothioate internucleotide linkage.
7 . The compound according to claim 5 , wherein the three [N] nucleotides of formula (A) are represented as 5′-[N1, N2, N3]-3′, wherein:
a. N1 is a 2′-deoxy-2′-fluoro nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxynucleotide; and
b. any of N1, N2, or N3 optionally comprises a phosphorothioate internucleotide linkage.
8 . The compound according to claim 5 , wherein the three [N] nucleotides of formula (A) are represented as 5′-[N1, N2, N3]-3′, wherein:
a. N1 is a 2′-deoxy nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-O-methyl nucleotide; and
b. any of N1, N2, or N3 optionally comprises a phosphorothioate internucleotide linkage.
9 . The compound according to claim 5 , wherein the three [N] nucleotides of formula (A) are represented as 5′-[N1, N2, N3]-3′, wherein:
a. N1 is a 2′-deoxy nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxy nucleotide; and
b. any of N1, N2, or N3 optionally comprises a phosphorothioate internucleotide linkage.
10 . The compound according to claim 5 , wherein the three [N] nucleotides of formula (A) are represented as 5′-[N1, N2, N3]-3′, wherein:
a. N1 is a 2′-deoxy-2′-fluoro nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxy-2′-fluoro nucleotide; and
b. any of N1, N2, or N3 optionally comprises a phosphorothioate internucleotide linkage.
11 . The compound according to claim 2 , wherein X1 is 2.
12 . The compound according to claim 2 , wherein X5 is 3, X1 is 2 and X2 is 2.
13 . The compound according to claim 2 , wherein said siNA molecule comprises one or more universal base substitutions.
14 . The compound according to claim 2 , wherein said double-stranded short interfering nucleic acid (siNA) molecule includes one or more locked nucleic acid (LNA) substitutions.
15 . The compound according to claim 2 , wherein one or more overhanging nucleotides of said siNA molecule is a 2′-O-methyl nucleotide.
16 . The compound according to claim 2 , wherein said double-stranded short interfering nucleic acid (siNA) molecule comprises at least one phosphorothioate internucleotide linkage.
17 . The compound according to claim 2 , wherein X5=3; each X1 and X2=1 or 2; X3=18, 19, 20, 21, 22, or 24, and X4=17, 18, 19, 20, 21, 22, or 23.
18 . The compound according to claim 2 , wherein X5=3; each X1 and X2=2; X3=19, and X4=16.
19 . The compound of claim 2 , wherein the 2′-O-alkyl nucleotide is a 2′-O-methyl nucleotide.
20 . The compound of claim 2 , wherein the 2′-halo nucleotide is a 2′-deoxy-2′-fluoro nucleotide.
21 . The compound of claim 2 , wherein five or more purine nucleotides in the N X4 positions are 2′-O-methyl nucleotides.
22 . The compound of claim 2 , wherein five or more pyrimidines in the N X4 positions are 2′-fluoro nucleotides.
23 . The compound of claim 2 , wherein five or more purine nucleotides in the N X3 positions are 2′-O-methyl nucleotides.
24 . The compound of claim 2 , wherein five or more purine nucleotides in the N X3 positions are 2′-fluoro nucleotides.
25 . The compound of claim 2 , wherein five or more pyrimidine nucleotides in the N X3 positions are 2′-fluoro nucleotides.
26 . The compound of claim 2 , wherein:
(a) 5, 6, 7, 8, 9, 10 or more of the pyrimidine and purine nucleotides in the N X4 positions are independently chosen from 2′-O-methyl nucleotides or 2′-deoxy-2′-fluoro nucleotides, or any combination thereof;
(b) 5, 6, 7, 8, 9, 10 or more of the pyrimidine and purine nucleotides in the N X3 positions are independently chosen from 2′-O-methyl nucleotides or 2′-deoxy-2′-fluoro nucleotides, or any combination thereof; and
(c) [N] position nucleotide(s) are any combination of ribonucleotides, deoxyribonucleotides, 2′-O-alkyl nucleotides, 2′-halo nucleotides, or any combination thereof irrespective of the purine or pyrimidine content.
27 . The compound of claim 2 , wherein at least 5 or more of the pyrimidine nucleotides in one or both strands are 2′-deoxy-2′-fluoro pyrimidine nucleotides and at least 5 or more purine nucleotides in one or both strands are 2′-O-methyl purine nucleotides.
28 . The compound of claim 2 , wherein at least 5 or more of the pyrimidine nucleotides in one or both strands are 2′-O-methyl pyrimidine nucleotides and at least 5 or more purine nucleotides in one or both strands are 2′-deoxy-2′-fluoro purine nucleotides.
29 . The compound of claim 2 , wherein said siNA molecule comprises one or more acyclic nucleotides.
30 . The compound of claim 2 , further comprising one or more phosphorothioate linkages between the first terminal (N) and the adjacent nucleotide on the 3′ end of the sense strand.
31 . The compound of claim 2 , wherein X1=2 overhanging nucleotide positions with a phosphorothioate internucleotide linkage.
32 . The compound of claim 2 , wherein the ligand is chosen from a steroidal compound, a galactosamine, a vitamin, a protein, a peptide, or an antibody.
33 . The compound of claim 32 , wherein the ligand is a cholesterol.
34 . The compound of claim 32 , wherein the ligand comprises one or more N-acetylgalactosamine.
35 . The compound of claim 32 , wherein the ligand is covalently attached to the siNA molecule via a linker.
36 . The compound of claim 2 , wherein one B comprises a delivery modality, wherein the delivery modality comprises the ligand and further includes one or more linker molecules.
37 . The compound of claim 35 , wherein the linker is chosen from a phosphate ester based linker, an amino based linker, a disulfide based linker, a succinyl based linker, an alkyl or substituted alkyl based linker, or an amide based linker.
38 . The compound of claim 2 , wherein the ligand is attached at the 5′-end of the sense strand.
39 . The compound of claim 2 , wherein the ligand is attached at the 3′-end of the sense strand.
40 . The compound of claim 2 , wherein
(a) all pyrimidine nucleotides in N X4 positions are 2′-O-methyl nucleotides;
(b) all purine nucleotides in N X4 positions are 2′-halo nucleotides;
(c) all pyrimidine nucleotides in N X3 positions are 2′-O-alkyl nucleotides;
(d) all purine nucleotides in N X3 positions are 2′-halo nucleotides; and
(e) [N] position nucleotide(s) are any combination of ribonucleotides, deoxyribonucleotides, 2′-O-alkyl nucleotides, or 2′-halo nucleotides;
(f) the nucleotide at position 14 from the 5′-end of the antisense strand is a 2′-deoxy-2′-fluoro nucleotide regardless of whether it is a purine or pyrimidine; and
(g) [N] nucleotides of formula (A) are represented as 5′-[N1, N2, N3]-3′, wherein
i) N1 is a 2′-deoxy nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxy nucleotide; or
ii) N1 is a 2′-deoxy-2′-fluoro nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxy-2′-fluoro nucleotide; or
iii) N1 is a 2′-deoxy-2′-fluoro nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-deoxynucleotide; or
iv) N1 is a 2′-deoxy nucleotide, N2 is 2′-deoxy-2′-fluoro nucleotide, and N3 is a 2′-O-methyl nucleotide; or
v) N1, N2, and N3 are all ribonucleotides having phosphorothioate internucleotide linkages.
41 . A composition comprising the siNA molecule according to claim 2 and a pharmaceutically acceptable carrier or diluent.